Mexico Cardiovascular Diseases Therapeutics Market Report 2022 to 2030

Mexico Cardiovascular Diseases Therapeutics Market Analysis

$ 3999

The Mexico cardiovascular disease therapeutics market is expected to witness growth from $2.44 Bn in 2022 to $4.34 Bn in 2030 with a CAGR of 7.47% for the year 2022-2030. The improvement in health infrastructure and spending and the development of new therapeutics in Mexico are responsible for the expansion of the market. The Mexico cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Liomont, Vitalmex, and Sanofi are the major players in the Mexico cardiovascular disease therapeutics market.

ID: IN10MXPH033 CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico AUTHOR: Dr. Parul Choudhary

Buy Now

Mexico Cardiovascular Disease Therapeutics Market Executive Analysis

The Mexico cardiovascular disease therapeutics market size is at around $2.44 Bn in 2022 and is projected to reach $4.34 Bn in 2030, exhibiting a CAGR of 7.47% during the forecast period. The federal government's proposed $417 Bn 2023 budget for Mexico includes a number of high-ticket items, including infrastructure projects, pensions for elderly citizens, health care, and social programs. The Ministry of Finance (SHCP) also included substantial health care expenditures. Major healthcare provider the Mexican Social Security Institute is expected to receive over $58 Bn, a rise of almost 10% from this year, while the Ministry of Health is expected to receive $11.04 Bn.

In Mexico, coronary heart disease accounts for 68.5% of deaths from cardiovascular disease (CVD), which accounts for about 20% of all fatalities. According to estimates, 4% of all health spending in 2006 went toward treating CVD. Mexico and the other 13 most populous mega-countries account for 65 % of all CVD deaths worldwide. These nations exhibit significant cultural diversity, varied economic potential, and various epidemiological and nutritional transitional phases.

The only treatments for atherosclerosis that are presently available are statins, ACE inhibitors, and beta-blockers, with statin being the most researched and used as first-line therapy. Stable compounds that can be used as targeting agents are therapeutic antibodies. They have a strong selectivity and affinity for binding to the target proteins. Current technical advancements in antibody engineering have made it possible for the successful translation of antibody drugs to the field, despite several limitations, including an unclear mode of action, ineffective tissue penetration, and impaired immune reactions. Currently, the US Food and Drug Administration (US FDA) has authorized more than 79 antibody medications, and more than 570 antibody therapies are being researched globally. Inflammation and cardiovascular diseases will both be greatly helped by the development of antibody medicines against pro-atherosclerotic factors.

Mexico Cardiovascular Disease Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

The quality of treatment and expanding access to healthcare have been the main goals of Mexico's rising healthcare spending in recent years. The Mexico cardiovascular disease therapeutics market is likely to increase as a result of this. The area of cardiovascular disease therapeutics is continually developing new technologies and treatment options. To combat the high prevalence of cardiovascular diseases in the nation, the Mexican government is aggressively promoting healthcare and investing in the research and development of new therapeutics. Market expansion is anticipated to be supported by government efforts like the Seguro Popular program and the National Health Program 2019–2024.

Market Restraints

The cost of treating cardiovascular disease may prevent people with lower incomes from accessing these treatments. This may hinder market expansion, especially in light of the rising expense of healthcare. Even though Mexico has made great strides in recent years to increase access to healthcare, there are still gaps in the system. The use and adoption of therapeutics for cardiovascular illness may be impacted by this. It's possible that many cardiovascular disease patients are unaware of the most recent therapeutic choices or the value of early intervention. Delays in diagnosis and treatment may occur as a consequence, which may have an effect on the Mexico cardiovascular disease therapeutics market's expansion.

Competitive Landscape

Key Players

Perrigo De Mexico (MEX)
Merz Pharma (MEX)
Neolsym (MEX)
Liomont (MEX)
Vitalmex (MEX)
Sanofi
Bayer
Bristol-Myers Squibb
Daiichi Sankyo
Johnson & Johnson
Gilead Sciences
Par Pharmaceutical
United Therapeutics

Healthcare Policies and Regulatory Landscape

The majority of Mexicans receive their healthcare services primarily from the state healthcare system, which is run by the Secretara de Salud (SSA) and the Instituto Mexicano del Seguro Social (IMSS). While the SSA is in charge of providing healthcare services to the rest of the population, including those who are self-employed or work in the informal sector, the IMSS is in charge of providing healthcare services to those working in the formal sector. Patients with cardiovascular diseases are qualified for a variety of healthcare services under these public healthcare systems, including For the treatment of cardiovascular diseases, a broad variety of drugs are addressed, including antiplatelets, anticoagulants, beta-blockers, ACE inhibitors, and statins. Government-set reimbursement rates for these services and medicines are open to adjustment in light of elements like service cost, inflation, and advancements in medical technology. Private health insurance is also offered in Mexico in addition to the state healthcare system, and it can offer supplemental coverage for treatments and services related to cardiovascular health. Private insurance coverage and reimbursement practices, however, can differ significantly based on the precise plan and supplier.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cardiovascular Disease Therapeutics Segmentation

By Disease Indication (Revenue, USD Billion):

Hypertension
Coronary Artery Disease
Hyperlipidaemia
Arrhythmia
Others

By Drug Type (Revenue, USD Billion):

Antihypertensive
Anticoagulants
Antihyperlipidemic
Antiplatelet Drugs
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Drug Classification (Revenue, USD Billion):

Branded Drugs
Generic Drugs

By Mode of Purchase (Revenue, USD Billion):

Prescription-Based Drugs
Over-The-Counter Drugs

By End Users (Revenue, USD Billion):

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.